Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Naoto TakahashiYoshihiro KameokaMakoto OnizukaYasushi OnishiFumiaki TakahashiTakashi DanToshio MiyataKiyoshi AndoHideo HarigaePublished in: Cancer medicine (2022)
in more patients than stand-alone TKI treatment.